On Monday, BMO (TSX:BMO) Capital maintained its Outperform rating and $234.00 price target for Alnylam Pharmaceuticals, traded on NASDAQ:ALNY. The firm's positive stance follows recent presentations on Zilebesiran, highlighting its potential as both a monotherapy and combination therapy for treatment-resistant hypertension.
Alnylam's Zilebesiran showcased promising blood pressure reductions when used in conjunction with standard-of-care (SoC) treatments. Over three months, the drug achieved systolic blood pressure reductions between approximately 4-12mmHg compared to baseline across three different SoC treatments. The safety profile of the drug was also considered acceptable.
The analyst from BMO Capital highlighted Zilebesiran's infrequent dosing schedule, which requires administration only every six months. This feature, along with its demonstrated efficacy, positions Zilebesiran as a potentially attractive treatment option in a market currently dominated by generic medications. The firm anticipates that Zilebesiran could achieve branded-name pricing due to these advantages.
Looking forward, BMO Capital is closely monitoring the upcoming KARDIA-3 data, expected in the second half of 2025, which is predicted to significantly impact cardiovascular outcome trials. In the near term, the HELIOS-B readout remains a key catalyst for Alnylam Pharmaceuticals.
InvestingPro Insights
As Alnylam Pharmaceuticals (NASDAQ:ALNY) continues to garner positive attention from BMO Capital due to its innovative hypertension treatment, Zilebesiran, recent data from InvestingPro highlights several key financial metrics and analyst insights that could influence investor perception. With a Market Cap of $19.67 billion and a significant Revenue Growth of 76.23% in the last twelve months as of Q4 2023, Alnylam's financial growth trajectory appears robust.
Despite not being profitable over the last twelve months, as indicated by a negative P/E Ratio of -44.10, the company's Gross Profit Margin remains impressive at 83.02%. This suggests that while the company is investing heavily in its research and development, it is able to maintain a high level of efficiency in its operations.
InvestingPro Tips for Alnylam Pharmaceuticals include the fact that analysts have revised their earnings upwards for the upcoming period, signaling confidence in the company's future performance. Additionally, Alnylam operates with a moderate level of debt and its liquid assets exceed short-term obligations, providing financial stability as it continues to develop its drug pipeline. It's noteworthy that while analysts do not anticipate the company will be profitable this year, the potential market differentiation of Zilebesiran could pave the way for future profitability.
For those seeking a deeper dive into Alnylam's financial health and future prospects, InvestingPro offers additional insights. With a total of 6 InvestingPro Tips available, investors can gain a more comprehensive understanding of the company's position. To access these insights, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at https://www.investing.com/pro/ALNY.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.